Invention Grant
- Patent Title: Antibodies against claudin 18.2 useful in cancer diagnosis
-
Application No.: US15227565Application Date: 2016-08-03
-
Publication No.: US10053512B2Publication Date: 2018-08-21
- Inventor: Ugur Sahin , Ozlem Tureci , Rita Mitnacht-Kraus , Stefan Woll
- Applicant: Ganymed Pharmaceuticals AG , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
- Applicant Address: DE Mainz DE Mainz
- Assignee: GANYMED PHARMACEUTICALS AG,TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
- Current Assignee: GANYMED PHARMACEUTICALS AG,TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
- Current Assignee Address: DE Mainz DE Mainz
- Agency: Neal, Gerber & Eisenberg LLP
- Agent Kevin A. O'Connor
- Priority: EPPCT/EP2012/001991 20120509
- Main IPC: A61K49/00
- IPC: A61K49/00 ; C07K16/00 ; C07K16/18 ; C07K16/28 ; C07K16/30 ; G01N1/00 ; G01N33/574 ; A61K51/10
Abstract:
The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
Public/Granted literature
- US20160333109A1 ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS Public/Granted day:2016-11-17
Information query
